医疗器械公司 波士顿科学 公布第三季度业绩,销售额同比增长20%至50.7亿美元,超出华尔街分析师预期的49.7亿美元。其中,心血管部门的销售额同比增长22%至33.4亿美元,高于预期的32.7亿美元。期内调整后每股收益为75美分,高于预期的71美分。
展望第四季度,公司预计每股收益将介于77至79美分之间,分析师预期为76美分。
对于今年全年,公司将调整后每股收益指引从2.95至2.99美元上调至3.02至3.04美元,分析师预期为2.98美元。
医疗器械公司 波士顿科学 公布第三季度业绩,销售额同比增长20%至50.7亿美元,超出华尔街分析师预期的49.7亿美元。其中,心血管部门的销售额同比增长22%至33.4亿美元,高于预期的32.7亿美元。期内调整后每股收益为75美分,高于预期的71美分。
展望第四季度,公司预计每股收益将介于77至79美分之间,分析师预期为76美分。
对于今年全年,公司将调整后每股收益指引从2.95至2.99美元上调至3.02至3.04美元,分析师预期为2.98美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.